News from skylinedx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 31, 2018, 09:04 ET SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma

SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making...


Dec 05, 2017, 08:00 ET SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler™ with SKY92 in Multiple Myeloma

SkylineDx today announced the presentation of new data at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH) in...


Nov 13, 2017, 09:05 ET SKY92 Gene Signature Facilitates Cost-effective, Risk-stratified Treatment of Multiple Myeloma

SkylineDx announced new data from the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)...


Oct 11, 2017, 11:44 ET SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial

SkylineDx today announced that The Institute of Cancer Research, London (ICR) and University of Leeds will use MMprofiler™ with SKY92, SkylineDx's...


Jul 25, 2017, 09:00 ET SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM)

SkylineDx today announced the publication of new data that validate the Company's SKY92 gene expression signature as a prognostic tool to evaluate...


Jun 20, 2017, 09:05 ET Data Presentations at European Hematology Association (EHA) 22nd Annual Congress Further Validate SkylineDx Prognostic Tools in Multiple Myeloma

kylineDx today announced the presentation of new data that validate the use of MMprofiler with SKY92, the company's prognostic tool to risk stratify...


Apr 10, 2017, 09:00 ET SkylineDx Presented New Algorithm Demonstrating Ability to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival

SkylineDx announced that they had developed TOPSPIN (Treatment Outcome Prediction using Similarity between PatIeNts) algorithm for identifying...


Nov 29, 2016, 10:17 ET SkylineDx Announces Multiple Studies Being Presented at the 58th Annual ASH Meeting Reinforcing Utility of MMprofiler™ Gene-Based Prognostic Signature to Impact Treatment of Patients with Multiple Myeloma

SkylineDx today announced the presentation of new data that demonstrate the prognostic value of MMprofiler™ SKY92 gene signature, a gene expression...


Oct 11, 2016, 11:01 ET SkylineDx Receives Notice of Allowance to Grant Patent for Prognostic SKY92 Gene Signature in Japan

SkylineDx is pleased to announce that it has received a notice of allowance for a Japanese patent related to its prognostic SKY92 gene signature for...


Oct 04, 2016, 11:25 ET SkylineDx and Consortium of Leading European Partners awarded multi-million Euro Horizon2020 grant from European Commission

SkylineDx today announced it has been awarded a multi-million euro Horizon2020 grant from the European Commission to develop a new, and novel...


May 31, 2016, 09:00 ET SkylineDx to Present New Data Demonstrating MMprofiler™ as Robust Prognostic Tool in Multiple Myeloma at the European Hematology Association 21st Annual Congress (EHA)

SkylineDx today announced the presentation of four posters that reconfirm the prognostic value of MMprofiler™ with SKY92, the only gene-based...


Mar 08, 2016, 09:00 ET SkylineDx Supports Myeloma Awareness Month to Raise Awareness of a Serious and Difficult to Treat Disease

SkylineDx today announces its support for Myeloma Awareness Month, an effort conducted throughout the month of March by the International Myeloma...


Dec 01, 2015, 09:00 ET SkylineDx to Present New Data Demonstrating Prognostic Value of MMprofiler™ in Multiple Myeloma at American Society of Hematology Annual Meeting

SkylineDx today announced the presentation of two posters that demonstrate the prognostic value of the MMprofiler™, SkylineDx's gene expression...


Nov 26, 2015, 05:41 ET SkylineDx ontvangt CE-IVD-markering voor MMprofiler™ -- haar innovatieve, op gensignatuur gebaseerde test voor multipel myeloom

SkylineDx, kondigde vandaag aan dat zij een CE-IVD-registratie hebben ontvangen van de European Competent Authority (Ministerie van Gezondheidszorg)...


Nov 26, 2015, 05:35 ET SkylineDx reçoit le marquage CE-IVD pour le MMprofiler™ -- son test innovant basé sur la signature génique pour le myélome multiple

SkylineDx a annoncé aujourd'hui qu'elle avait reçu l'enregistrement CE-IVD de l'Autorité européenne compétente (ministère de la Santé) pour le...


Nov 25, 2015, 10:13 ET SkylineDx erhält CE-IVD Kennzeichnung für den MMprofiler™ -- seinen innovativen, auf Gensignaturen aufbauenden Test für multiples Myelom

SkylineDx gab heute bekannt, man habe von der zuständigen europäischen Behörde (Gesundheitsministerium) die CE-IVD Registrierung für den MMprofiler™...


Nov 25, 2015, 09:00 ET SkylineDx recibe la Marca CE-IVD para MMprofiler™ -- Su innovador test de gen basado en firma para mieloma múltiple

SkylineDx anunció hoy que ha recibido el registro CE-IVD de la European Competent Authority (Ministerio de Sanidad) para MMprofiler™, el test de...


Nov 25, 2015, 09:00 ET SkylineDx Receives CE-IVD Mark for MMprofiler™ -- Its Innovative Gene Signature-Based Test for Multiple Myeloma

SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Ministry of Health) for the MMprofiler™, the ...